Effect of Combining Early Chemotherapy with Zhipu Liujunzi Decoction under the Concept of Strengthening and Consolidating Body Resistance for Gastric Cancer Patients and Nursing Strategy

Abstract

Objective. To explore the clinical efficacy of combining early chemotherapy with Zhipu Liujunzi decoction under the concept of strengthening and consolidating body resistance for gastric cancer patients and nursing strategy. Methods. The clinical data of 100 patients undergoing radical gastrectomy in our hospital from July 2019 to July 2020 were selected for the retrospective analysis, and the patients were divided into the control group and experimental group according to different treatment methods, with 50 cases in each group. Early chemotherapy after surgery was given to patients in the control group, and on the basis of the aforesaid treatment and under the concept of strengthening and consolidating body resistance, patients in the experimental group took Zhipu Liujunzi decoction and received the nursing strategy, so as to compare their effective rate, adverse reaction rate (ARR), immune function indicators, KPS scores, and nursing satisfaction scores. Results. After treatment, the experimental group obtained significantly higher objective remission rate (ORR) and disease control rate (DCR) ( $P<0.05$ ), lower carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels ( $P<0.001$ ), higher immune parameters levels ( $P<0.001$ ), higher KPS scores and lower TCM symptom scores ( $P<0.001$ ), lower PSQI scores, SAS scores, and SDS scores ( $P<0.001$ ) and higher nursing satisfaction scores ( $P<0.001$ ), and lower total accidence rate of toxic side effects ( $P<0.05$ ) than the control group. Conclusion. Under the concept of strengthening and consolidating body resistance, combining early chemotherapy with Zhipu Liujunzi decoction is a reliable method for improving the immune function and quality of life for gastric cancer patients with higher safety. Such a strategy greatly reduces the tumor marker levels in patients. Further research will be conducive to establishing a better solution for gastric cancer patients.